JOHN SNINSKY

Ph.D., Chief Scientific Officer, CareDx Inc.

John Sninsky, Ph.D. joined CareDx Inc. as Chief Scientific Officer in January 2015. CareDx, Inc., based in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value, non-invasive diagnostic surveillance solutions for transplant recipients. John brings a wealth of experience in the discovery, development and application of diagnostic technologies, content and interpretive test solutions ranging from early stage biotechnology to international pharmaceutical organizations as well as a range of CLIA and IVD product settings. He was instrumental in the early development of PCR and companion diagnostics tests for HIV while at Cetus Corp. and Roche Molecular Systems. John oversaw early functional genetic association studies for common complex disease while serving as V.P. of Discovery Research at Celera. Following Celera's acquisition by Quest Diagnostics, he served as the Alameda site head for Quest's Science & Innovation and oversaw organization-wide Bioinformatics. John received a B.S. in biology from Bates College, a Ph.D. in biology from Purdue University and was a postdoctoral fellow in Genetics and Medicine at Stanford University School of Medicine. John was on the faculty at Albert Einstein College of Medicine (AECOM) in the Department of Microbiology and Immunology with a joint appointment in the Department of Molecular Biology as well as a member of the AECOM Liver and Cancer Centers.

 

Sesion: Personalized Medicine in Organ Transplantation

Patients who have undergone organ transplants require frequent monitoring to evaluate the organ’s graft status and to modulate a complex regimen of immunosuppressive medications. The earliest detection of immune activation and graft injury followed by therapeutic intervention leads to better outcomes. Today, noninvasive, molecular diagnostics using predictive biomarkers can detect the earliest signs of rejection, even weeks to months before functional failure, and pinpoint actionable causes, enabling precision modulation of therapy and improved outcomes in organ transplantation. In this session you’ll hear from three leaders who are at the forefront of developing commercialized molecular diagnostics for heart and kidney transplantation.

 

Web Analytics